Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus

AZ and Sanofi’s Antibody Success Against The Often Deadly Infection

 
• By Andrew McConaghie

Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.

Boy_Inhaler
Respiratory synctial virus (RSV) is one of the biggest causes of hospitalization and death in infants worldwide.

More from Business

More from Scrip